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ABSTRACT
Background: Heart failure is a major public health 
problem and has been recognized as an important cause of 
morbidity and mortality for several years. It is one of the 
leading non-infectious causes of death among 
hospitalized patients at the University Teaching Hospital 
(UTH) in Lusaka, Zambia. This study aimed to 
investigate the predictors of 30-day mortality in heart 
failure patients admitted to the medical wards at the UTH 
using routinely obtained clinical data.
Methods: We enrolled 390 heart failure patients and 
followed them up over a period of 30 days. Data collected 
included demographic characteristics (age, sex), 
medication use and co-morbidities (hypertension, 
diabetes mellitus, Human Immunodeficiency Virus 
(HIV) infection). Clinical data included vital signs, blood 
urea, serum sodium, serum potassium, serum creatinine, 
and haemoglobin level. Trans-thoracic echocardiographs 
and electrocardiographs were also done to determine left 
ventricular ejection fraction (LVEF) and to check for the 
presence of arrhythmias. Patients were dichotomized into 
those with preserved (LVEF>=40 percent) and reduced 
(LVEF< 40 percent) systolic function. Recruited patients 
were then prospectively followed up to determine 
outcome by day 30 (i.e. dead or alive). Cox proportion 
Hazard regression analysis (on Epi Info software version 
3.5.3) was used to analyse the effect of each of these 
parameters on outcome.
Results: Of the recruited patients, 59% were female (95% 
CI 54-64). The median age was 50 years (IQR 33-68). 138 
patients (35%, 95% CI 31-40) died within 30 days of 
admission. 94 (68%) of these deaths occurred in-hospital. 
The factors shown to be independent predictors of death 
onmultivariate logistic regression analysis were 
LVEF<40 percent (OR=2.86, 95%CI 1.68- 4.87), NYHA 
class IV (OR=2.15, 95%CI 1.27- 3.64),serum urea above 
15mmol/L (OR=2.48, 95%CI 1.07-5.70), and 
haemoglobin level below 12g/dL (OR=1.79, 95%CI 1.11-
2.89).The additional factor associated with increased risk 
of mortality on univariate analysis wassystolic blood 
pressure below 115mmHg (OR=1.63, 95%CI 1.05- 2.51). 
However, serum creatinine (OR=1.49, 95%CI 0.49-4.48) 
and HIV seropositivity (OR=0.96, 95% CI 0.53-1.72)had 
no bearing on the risk of death in this patient population.
Conclusions:  Left ventricular ejection fraction <40 
percent, New York Heart Association class IV, serum urea 
above 15mmol/L, haemoglobin level below 12g/dLand 
systolic blood pressure below 115mmHg are predictors of 
poor 30-day outcome in hospitalised heart failure 
patients.
BACKGROUND
The clinical syndrome of heart failure is characterised by 
dyspnoea, fatigue, and fluid retention which may develop 
1, 2as a consequence of cardiac disease.  The aetiology is 
3 varied and ultimately results in impaired diastolic or 
systolic function.
Heart failure is an important public healthproblem. It has 
been recognised for several years as one of the major 
3,4causes of morbidity and mortality worldwide.  The 
burden of heart disease and cost of management of 
4,5patients is high.  In North America almost 20 percent of 
admissions to hospital are due to heart failure and 
5between 2.1 and 22 percent of these patients die.  In 
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Europe heart failure accounts for 5 percent of admissions 
to hospital medical wards and the mortality is estimated at 
6about 13 percent.  Unfortunately, the magnitude of this 
problem in Africa is not well studied as few population-
based studies have been done on the prevalence of heart 
failure and the mortality rates. 
The use of prognostic indicators in predicting disease 
progression and the probability of death is important in 
clinical practice. Early recognition and treatment of 
reversible factors indicative of a poor outcome could aid 
in reducing deaths. 
Several studies done in different populations have 
reached varying conclusions regarding the most accurate 
predictors of mortality in heart failure patients. Some of 
these studies are population-based and describe the long-
term probability of death. Such a study is the landmark 
Framingham heart failure study, a long-term follow-up 
study started in the 1940s. This study as well as 
subsequent studies which used data derived from it 
helped highlight the importance of prognostication in 
heart failure. Most recently, studies on prognosis in heart 
failure have focused on the identification of factors which 
are likely to be indicative of a poor outcome in 
hospitalised patients. These studies utilise data which is 
routinely collected on patients' admission to hospital in 
order to aid clinicians triage patients and provide effective 
intervention measures. 
The clinical prognostic determinants in heart failure can 
be categorised into the following: (1) patient 
characteristics and co-morbidities; (2) laboratory 
parameters; (3) functional parameters and ventricular 
7, 8function; and (4) interventions received.
Some of the documented independent factors associated 
with high risk of death in heart failure patients include the 
patient's age, sex, heart rate, blood pressure, New York 
Heart Association (NYHA) class, haemoglobin (Hb) 
level, serum sodium, serum urea, serum creatinine, 
presence of arrhythmias, and the left ventricular ejection 
fraction (LVEF). Recently, the use of biomarkers (Brain 
Natriuretic Peptide, Cystatin C, Troponin T and Growth 
differentiation factor 15) to predict mortality has been 
investigated, particularly in the Western world with 
varying conclusions regarding the biomarker with the 
most accurate prediction of poor outcome.
For several years, heart disease has been one of the major 
causes of morbidity and mortality at the University 
Teaching Hospital (UTH). Hospital records indicate that 
the proportion of deaths has increased from 30 percent to 
44percent in the last ten years. The aim of this study was to 
establish some of the factors associated with 30-day 
mortality in patients admitted with heart failure at the 




This was was a cohort study with a follow-up period of 30 
days.
Study setting and population
This study was conducted in the admitting medical wards 
at the UTH in Lusaka. Enrolment and follow-up of 
patients was done between November 2010 and 
September 2011. Patients above the age of 18 years who 
gave written consent and met the case definition of heart 
failure according to the European Society of Cardiology 
guidelines were recruited into the study. Patients with 
pericardial effusion and constrictive pericarditis were 
excluded (definitive management these patients would 
involve either  drainage of fluid from the pericardial space 
or pericardectomy, and treating the underlying cause as 
opposed to administering standard anti-failure 
medication).
Clinical Procedure
Study patients were recruited from the admitting medical 
wards. Written consent was then obtained from eligible 
patients who met the diagnostic criterion of heart failure. 
Information gathered included patient demographic 
characteristics (age, sex, contact phone number), 
previous and current anti-failure medication use, past 
medical history, functional status (NYHA class) and 
admission vital signs (blood pressure (BP), heart rate, 
respiratory rate, and axillary temperature). Blood was 
collected from each patient for blood urea, electrolytes 
(sodium, potassium), creatinine, and Hb level soon after 
hospitalisation for analysis. 
LVEF was determined using 2-dimensional trans-
thoracic echocardiography (ECHO) set in motion-mode 
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from left parasternal long axis views. Patients were 
dichotomised as either having reduced systolic function 
(LVEF<40 percent) or preserved systolic function 
(LVEF>=40 percent). Electrocardiography (ECG) were 
also done on admission and reported on independently by 
two clinicians. Arrhythmias and conduction defects such 
as atrial fibrillation (AF) or flutter, left bundle branch 
block (LBBB), right bundle branch block (RBBB), 
premature ventricular contractions (PVCs), and Long 
QTc were documented.
Outcome
Patients were followed up on a daily basis while in 
hospital. Discharged patients were reviewed in the 
outpatient clinic and/or contacted by phone at day 30 to 
determine outcome (i.e. dead or alive). Data collected was 
then entered into epi info software and analysed.
Data analysis
All statistical analysis was done using epi info version 
3 . 5 . 3  d a t a s e t  a t  9 5  p e r c e n t  c o n f i d e n c e  
interval.Continuous variableswith Gaussian distribution 
were expressed as means and standard deviation. The 
student t-test was used to test for statistical significance. 
Continuous variables with non-Gaussian distribution 
were expressed as medians and inter-group differences. 
Kruskal-Wallis test was used in this group to test for 
statistical significance. Categorical variables were 
expressed as percentages or proportions. Chi-square test 
was used to measure the effect of each categorical 
variable (e.g. LVEF, sex) on the outcome (dead or alive at 
day 30). Some of the continuous variables (e.g. Hb, 
systolic blood pressure (SBP), diastolic blood pressure 
(DBP), serum creatinine) were dichotomised before 
analysis based on values obtained from previous studies. 
Univariate and multivariate logistic regression analysis 
was used to analyse the effect of each of the prognostic 
features (e.g. age, sex, LVEF) on outcome in heart failure 
patients (i.e. dead or alive). Cox proportion hazard 
regression analysis was also used for time-to-event 
analysis and to determine crude hazard ratios.
Study definitions
For the purpose of this study the following definitions 
were used.
Heart failure case definition:
As adapted from the 2008 European Society of 
2Cardiology (ESC) Guidelines
1. Symptoms (and signs) of heart failure at rest or during 
exercise. These include fatigue, breathlessness and 
congestion of systemic veins (orthopnoea, 
paroxysmal nocturnal dyspnoea, bilateral fine basal 
crepitations, dependent peripheral oedema, raised 
jugular venous pressure, and hepatomegaly), and
2. Objective evidence (preferably by echocardiography) 
of cardiac dysfunction (systolic or diastolic) at rest.
Reduced- or preserved systolic function
The cut-off of 40 percent for LVEF used in this study to 
categorise heart failure patients as having either reduced 
or preserved systolic function was adopted from a 
validated multicentre risk stratification study done in 
more than 100,000 hospitalised heart failure patients in 
9,10the United States of America.  One of the few 
documented African heart failure studies on prognosis 
11also utilised the LVEF cut-off of 40 percent.
Reduced systolic function: LVEF less than 40 percent; 
Preserved systolic function: LVEF greater than or equal to 
40 percent.
Low systolic blood pressure, high serum urea and 
creatinine
Similarly, the cut-offs for systolic blood pressure, serum 
urea, and serum creatinine were adopted from the 
validated risk stratification study mentioned above. High 
risk patients were identified as having the following 
10abnormal admission parameters:
Low systolic blood pressure: Systolic blood pressure less 
than 115mmHg
High serum urea: Serum urea above 15mmol/L.
High serum creatinine: Serum creatinine above 
243µmol/L.
Hyponatremia and hypokalemia (2008 ESC 
2Guidelines)
Serum sodium below 135mmol/L.and serum potassium 
below 3.5mmol/L respectively.
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2 12Anaemia(2008 ESC Guidelines  and W.H.O definition)
Haemoglobin level below 12g/dL in females and less than 
13g/dL in men.
New York Heart Association functional classification
Adapted from the recommendations made by the Criteria 
13Committee of the New York Heart Association of 1994:
1. Class I: No limitation of physical activity. 
Ordinary physical activity does not cause undue 
fatigue, palpitation, or dyspnoea.
2. Class II: Slight limitation of physical activity. 
Comfortable at rest, but ordinary physical 
activity results in fatigue, palpitation, or 
dyspnoea.
3. Class III: Marked limitation of physical activity. 
Comfortable at rest, but less than ordinary 
activity results in fatigue, palpitation, or 
dyspnoea.
4. Class IV: Unable to carry out any physical 
activity without discomfort. Symptoms at rest. 
If any physical activity is undertaken, 
discomfort is increased.
RESULTS
A total of 409 patients were approached as potential 
candidates for inclusion into the study. Of these, 7 refused 
to give consent. 3 patients were excluded on the basis of 
having pericardial disease and 1 had no contact details for 
follow-up (see Fig. 1). 94 patients died while in hospital. 
Of the discharged patients, 13 were lost to follow-up and 
44 were dead by day 30 with a median time-to-death of 14 
days (IQR= 7-25 days). 
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Baseline characteristics of the participants 
Patient demographics and clinical findings are shown in 
Table 1 and described briefly here. Majority of the 
patients were female (59%; 95% CI 54-64). The patients' 
mean age was 48years and 50 years for males and females 
respectively (p=0.927). 88 patients were HIV positive 
(23%; 95% CI 19-27).
Table 1: Baseline characteristics of heart failure patients 
and laboratory measurements
163 (42%, 95% CI 37-47) of the patients had an LVEF 
below 40% on trans-thoracic echocardiography. There 
was no statistically significant difference in age, NYHA 
class, HIV status or comorbidities such as diabetes or 
hypertension between those with reduced and preserved 
LVEF. As expected, patients with reduced LVEF had 
lower blood pressures and higher heart rates on 
admission. A significant proportion of patients with 
reduced LVEF had dilated cardiomyopathy as the 
underlying cardiac pathology. Those with preserved 
LVEF had either hypertensive heart disease, 
corpulmonale or valvularheart disease.
The median values for blood urea, creatinine, sodium, 
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24 (20-28) 22 (20-26) 0.013*





















Urea, mmol/L 6.7 (4.8-10.1) 7.0 (4.8-10.3) 6.3 (4.8-10) 0.506
Creatinine, µmol/L 100 (73-131) 98 (71-118) 102 (74-143) 0.076
Sodium, mmol/L 135 (132-140) 135 (131-139) 136 (132-141) 0.123
Potassium, mmol/L 3.86 (3.40-4.42) 3.73 (3.31-4.37) 3.91 (3.46-4.50) 0.267
Anaemia (Hb <12g/ dL) 166 (43) 69 (42) 97 (43) 0.937
Data are expressed as median (IQR) unless stated otherwise
* Statistically significant 
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failure patients with reduced LVEF and those with 
preserved LVEF.
Table 2: Previous and admission medication
Most of the previously diagnosed heart failure patients 
were on a combination of loop diuretics with ACEI (or 
ARBs) and/or aldosterone antagonists. Only 8 patients 
were on â blockers (Carvedilol) for chronic heart failure. 
Loop diuretics and ACEIs/ ARBs were more commonly 
prescribed in patients with LVEF>=40 percent on 
admission. Those with LVEF<40 percent were more 
likely to receive dopamine and digoxin than those with 
preserved systolic function. 
Outcome and Predictors of 30 day mortality
Table 3: Outcome of heart failure patients within 30 
days of admission




     
Loop diuretic                                  65 (40)                      95 (42) 0.696                                  
      
Angiotensin Converting Enzyme
 
Inhibitor                                                                                                      
(ACEI) or Angiotensin Receptor Blocker      55 (34)         68 (30) 0.428(ARB)
 
      
Aldosterone antagonist                 21 (13)                      25 (11) 0.573
      
â
 




       
Loop diuretic                              120 (74)                   188 (83)          0.028*
       
ACEI or ARB86 (53)                   144 (63)                      0.035*
Aldosterone antagonists               31 (19)                     37 (16)   0.486
â Blockers                                      2 (1.2)              5 (2.2)     0.475
Digoxin                                         52 (32)                     52 (23)     0.048
Aspirin                                           49 (30)                  76 (34)           0.476
Dopamine                                      39 (24)                     22 (10)          <0.001*
Data are expressed as number (percent)
*Statistically significant 
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Data are expressed as number (percent); *Statistically 
significant 
Figure 2: Predictors of death (Crude Hazard Ratios 
on Cox Proportion Logistic Regression) 
0.1 1 10
Corpulmonale:N=42










* Systolic blood pressure<115mmHg: N=234









1.89 (0.70 -5.11) 
0.58 (0.31 -1.12)
1.95 (1.39 - 2.72)*
1.32 (0.69 - 2.51)
2.10 (1.32 -3.30)*
1.02 (0.67 - 1.57)
1.19 (0.83 - 1.70)
1.43 (1.03 -2.00)*
1.51 (1.06 - 2.51)*
1.92 (1.27 - 2.91)*
0.97 (0.65 - 1.45)
1.31 (0.92 -1.86) 
0.83 (0.36 -1.93)
0.78 (0.56 -1.09)
1.28 (0.74 -2.23 )
N=number; *Statistically significant
Table 4: ECG findings and the probability of death 
Variable  Crude OR  95% CI Adjusted OR 95% CI



























1 .93 1 .86 0.46 -7.59
Long QTc 0.50 0 .07 - 3 .5 8 0 .4 5 0.05 - 4.07





All-cause mortality was 35 percent with most of these 
deaths occurring in hospital (see Table 3). The factors 
shown to be predictive of death on both univariate and 
multivariate logistic regression analysis, and cox 
proportion hazard regression analysis (see Figure 2 and 
3) were LVEF<40 percent (OR=2.86, 95%CI 1.68- 4.87), 
NYHA class IV (OR=2.15, 95%CI 1.27- 3.64), serum 
urea above 15mmol/L (OR=2.48, 95%CI 1.07-5.70), and 
Hb below 12g/dL (OR=1.79, 95%CI 1.11-2.89). The 
additional factor associated with increased risk of 
mortality on univariate analysis was SBP below 
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115mmHg OR=1.63, 95%CI 1.05- 2.51). However, 
serum creatinine (OR=1.49, 95%CI 0.49-4.48), the use of 
dopamine on admission (OR=1.52, 95% CI 0.79-2.91), 
and HIV status (OR=0.96, 95% CI 0.53-1.72) had no 
bearing on the risk of death in this patient population. The 
underlying cardiac abnormality was not associated with 
increased risk of death.
A few patients had conduction defects and arrhythmias. 
The most frequent findings on ECG were PVCs (n=30, 14 
percent) and AF (n=18; 8 percent). Only 8 of the patients 
we studied had LBBB. However, these findings were not 
associated with an increased risk of death (see Table 4).
DISCUSSION
Our patient population was mostly female and younger by 
almost 20 years compared to other cohorts studied in the 
10North America.  This finding was similar to other studies 
11, 14done in Uganda and Nigeria  and was probably due to 
the higher proportion of valvular heart disease and dilated 
cardiomyopathy (presumed to be of infective cause) in 
our patient population compared to coronary artery 
disease which is found predominantly in males (and 
1postmenopausal females) in western settings. HIV sero-
prevalence in our study population at 23 percent was 
higher than in the general Zambian population. HIV 
seropositivity however, was not associated with increased 
risk of death. The underlying cardiac condition was not 
associated with increased risk of death.The proportion of 
patients with ischaemic heart disease was small and this 
could be an underestimate. Some patients may have 
erroneously been labelled as having cardiomyopathy. 
With the lifestyle changes noted amongst the affluent 
African population, ischaemic heart disease needs to be 
thoroughly explored in our patient population.
The proportions of deaths in our patient population during 
the follow-up period was quite high at 35 percent (n=138). 
This was much higher than the in-hospital mortalities 
recorded in other studies (i.e. 3 to 4.1 percent). The 
magnitude of deaths was also 3 fold higher than that 
documented in a Nigerian study in patients who were 
11followed-up for a period of 6 months.   However, the 
authors acknowledged that the study's sample size of 79 
patients was quite small. Being a tertiary health 
institution, most of the patients who present to the 
University Teaching Hospital are critically ill patients 
referred from primary health care centres and second-
level hospitals. In addition, most of the patients present 
late to health care facilities further contributing to a delay 
in diagnosis and treatment. Finally, most of our heart 
failure patients, including those who could benefit from 
cardiac surgery, have limited access to anti-failure 
medication as the only readily available treatment option. 
None of the heart failure patients followed up with poor 
systolic function had access to intracardiac defibrillators 
or cardiac transplant. This could explain the higher 
mortality in patients with poor systolic function in our 
setting compared to the rest of the world where patients 
have better access to optimal medical therapy and 
potentially life-saving surgical interventions.
The independent prognostic predictors of mortality 
determined from our study included LVEF<40 percent, 
NYHA class IV, serum urea above 15mmol/L,and Hb 
below 12g/dL. SBP below 115mmHg were also indicative 
of poor outcome within the 30 day period of follow-up.
The proportion of heart failure patients with LVEF<40 
percent from our study was 42 percent (n= 163). This 
finding was similar to studies done in the developed 
10, 15world which found that about half of the admitted heart 
failure patients had reduced systolic function on trans-
thoracic echocardiography. The majority of the long-term 
follow-up studies done in North America as well as two 
studies done in Brazil and Nigeria found that patients with 
LVEF below 40 percent had worse outcomes. However, 
unlike our study, these studies had varied periods of 
follow-up ranging between three and six months. Most of 
these studies recruited chronic stable heart failure patients 
who were monitored and treated on out-patient basis. 
Despite the differences in patient populations and periods 
of follow-up, we found that LVEF less than 40 percent 
was an important independent prognostic factor in the 
patients we studied. 
The proportion of the heart failure patients recruited with 
anaemia was slightly lower than was estimated in other 
16studies on hospitalised patients.  Anaemia however, was 
an independent prognostic determinant of 30-day 
mortality in our patient population.Even mild degrees of 
anaemia are associated with worsened symptoms, 
functional status and survival particularly in patients with 
17,18poor myocardial reserve.
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The prognostic value of high NYHA class has mainly 
been echoed in long-term follow-up studies on heart 
failure and not in studies on in-hospital mortality. 
However, this factor could be of prognostic significance 
as NYHA class IV on admission indicates poor functional 
status and significant pulmonary congestion in patients 
who present with acute decompensation of chronic heart 
failure. 
10According to a study done by Fonarow et al  in-hospital 
mortality was higher in heart failure patients who had 
systolic blood pressure below 115 mmHg, serum urea 
above 15mmol/L and serum creatinine above 
243µmoL/L. The prognostic value of these factors was 
independent of the patients' LVEF. The predictability of 
high blood urea in prognosis was also in keeping with the 
15findings in Petersen's study.  However, high serum 
creatinine was not found to be an important prognostic 
factor in our study on analysis, even after adjusting for 
other variables. The contribution of poor renal function to 
worsening cardiac function and increased risk of death, 
however, was not fully explored as estimation of 
creatinine clearance or glomerular fitration rates were not 
done due to logistical problems. It is therefore difficult to 
conclude from these findings that cardio-renal syndrome 
does not play a role in the deaths of these patients.
The median serum sodium level of 135 mmol/L and 
serum potassium level of 3.8mmol/L in our patients was 
10, 19comparable to the findings in other Western studies . 
Some of our patients however, had deranged electrolyte 
profiles. 19 percent of the patients in this study had 
hyponatremia and 30 percent had hypokalaemia of 
varying degrees. Despite these findings, hyponatremia 
and hypokalaemia did not contribute to increased risk of 
death in the patients we studied. 
The low number of patients found to have arrhythmias or 
conduction defects may not be reflective of the actual 
magnitude of the problem in our heart failure patients as 
none of the patients we studied had access to continuous 
cardiac monitoring. Potentially fatal arrhythmias may not 
have been detected during their hospitalisation. 
Therefore, the data obtained refuting an association 
between an increased risk of death in patients with atrial 
fibrillation and LBBB, in line with major studies, may be 
inaccurate.
STUDY LIMITATONS
None of the patients had continuous monitoring of cardiac 
rhythm even whilst in hospital due to the limited number 
cardiac of monitors for inpatients and lack of ambulatory 
ECG devices for outpatients in order to detect 
arrhythmias. 
Considering that all-cause mortality was used as one of the 
end-points and that the study protocol did not include 
post-mortems, it is possible that some deaths may not have 
been due to cardiovascular cause, contributing to the high 
mortality reported in this study.
Some important prognostic indicators were not tested for 
in this study due to limited resources (i.e. cardiac 
biomarkers such as BNP, cystatin c and troponins). 
The information regarding the predictors of long term 
prognosis in the heart failure patients we studied was not 
obtained due to the limited follow-up period.
CONCLUSION AND RECOMMENDATIONS
In conclusion, mortality amongst hospitalised heart 
failure patients at the University Teaching Hospital in 
Lusaka, Zambia is high.
LVEF less than 40 percent was found to be a predictor of 
30 day mortality in hospitalised heart failure patients at the 
UTH. Other factors such as NYHA class IV, low systolic 
blood pressure, high serum urea and anaemia also 
increased the risk of death of 30 day mortality.
In view of the high mortality, we recommend that patients 
be triaged according to risk utilising the factors identified. 
In order to improve survival, heart failure patients who are 
at low- or high risk of death need regular monitoring so 
that potentially life-saving measures can be instituted 
when feasible.
Patients should have ready access to echocardiography 
and laboratory services as soon as they are admitted to the 
emergency medical wards. LVEF, Hb levels, and serum 
urea should be routinely measured in all heart failure 
patients. NYHA class must be documented and accurate 
blood pressure measurements taken on all in-patients in 
order to assess the risk of mortality
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Patients with LVEF less than 40 percent with refractory 
heart failure and cardiogenic shock should have access to 
implantable cardioverter defibrillators and cardiac 
transplant in order to aid improve survival.
Early referral of heart failure patients to tertiary health 
institutions for evaluation and management should be 
encouraged as late presentation to hospital could have 
contributed to the high mortality reported in this study. 
We also recommend that public health awareness be 
increased on the need for patients to seek medical help 
early in order to reduce mortality rates. 
A long term follow-up study on outcome in our patient 
population with heart failure needs to be done. The state 
of debility and outcome of these patients post-discharge 
remains largely unknown. With the current pressure on 
the few available medical resources in the healthcare 
system and the human resource crisis, it would be prudent 
to conduct a long-term follow-up study in order to 
determine ways of improving healthcare delivery for our 
heart failure patients in Zambia.
Further studies on cardiac biomarkers such as brain 
natriuretic peptide, troponins, and cystatin C ought to be 
done in order to determine the contribution of these 
factors to prognosis in our patient population.
ACKNOWLEDGEMENTS
This research would not have been possible without the 
contribution of Dr L. Hachaambwa and the staff at the 
UTH HIV Medicine Teaching Laboratory who provided 
the necessary laboratory support. We would also like to 
thank those working in the ECHO/ECG lab at the UTH. 
Finally, we greatly appreciate the participation of the 
heart failure patients we enrolled and their relatives for 
graciously accepting to be part of this study. 
REFERENCES
1. NHS Guidelines: Management of Chronic Heart 
Failure in Adults in Primary and Secondary care. 
www.nice.orgc.uk. 2010
2. ESC Guidelines for the Diagnosis and Treatment of 
Acute and Chronic Heart failure. Eur Heart J 2008. 
29: 2388-2442
3. American Heart Association: American Stroke 
Association. Heart disease and stroke statistics 
update. www.americanheart.org. 2004.
4. Ho K, Pinsky J, Kannel W, Levy D. The Epidemiology 
of Heart Failure: the Framingham study. J Am Coll 
Cardiol 1993; 22:6A
5. Jessup M. Heart Failure. NEJM 2003; 348:2007-2018.
6. Velavan P, Khan N, Goode K. Predictors of Short-term 
Mortality in Heart Failure- Insights from the Euro 
Heart Survey. Int J Cardiol 2010; 138:63-69.
7 Levy W, Mozaffarian D, Linker D, Sutradha S, Anker 
S, Cropp A, et al. The Seattle Heart Failure Model. 
Circ 2006; 113: 1424-1433.
8. Mosterd A, Hoes A. Clinical epidemiology of heart 
failure. Heart 2007; 93: 1137-1146.
9. Somaratne J, Berro C, Mc Murray J, Poppe K, 
Doughty R, Whalley G. The Prognostic Significance 
of Heart Failure with Preserved Left Ventricular 
Ejection Fraction. Eur J of Heart Fail 2009: 11; 855-
862.
10. Fonarow G, Adams K, Abraham W, Yancy C, 
Boscardin W. Risk stratification for in-hospital 
mortality in acutely decompensated heart failure: 
classification and regression tree analysis. JAMA 
2005; 293: 572–580.
11. Karaye K, Sani M. Factors associated with poor 
prognosis among patients admitted with Heart Failure 
in a Nigerian tertiary medical centre. BMC 
Cardiovasc disord 2008; 8:16.
12. Worldwide Prevalence of Anaemia 1993-2005. 
W.H.O global database on anaemia. ISBN 978 92 4 
159665 7.
13. The Criteria Committee of the New York Heart 
Association. Nomenclature and Criteria for Diagnosis 
of Diseases of the Heart and Great Vessels. 9th ed. 
Little Brown & Co1994. p 253–256
14. Amoah A, Kallen C. Aetiology of Heart Failure as 
seen from a Cardiac Referral Centre in Africa. 
Cardiology 2000; 93:11-8.
15. Peterson P, Rumsfeld J, Liang L, Albert L, Hernandez 
A, Petersen E, et al. A Validated Risk Stratification 
Score for In-Hospital Mortality in Patients with Heart 
Failure from the American Medical Association Get 
With The Guidelines Programme. Circ 2010; 3:25-32
Medical Journal of Zambia, Vol. 41, No. 1 (2014)
11
16. LindenfeldJ. Prevalence of anemia and the effects on 
mortality in patients with heart failure. Am Heart J 
2005; 149:391-401
17. Silverberg D, Wexlerb D, Iaina A, Schwartz D. The 
interaction between heart failure and other heart 
disease and anemia. Semin Nephrol 2006; 26: 296-
306.
18. Horwich T, Fonarow G, Hamilton M, MacLellan W, 
Borenstein J. Anemia is associated with worse 
symptoms, greater impairment in functional capacity 
and a significant increase in mortality in patients with 
advanced heart failure. Circ 2006; 113: 2713-2723.
19. Abraham W, Fonarow G, Albert N, Stough W, 
Gheorghiade M, Greenberg B, et al. Predictors of in-
hospital mortality in patients hospitalized for heart 
failure: insights from the Organized Program to 
Initiate Lifesaving Treatment in Hospitalized Patients 
With Heart Failure (OPTIMIZE-HF). J Am Coll 
Cardiol 2008; 52: 347–356
Medical Journal of Zambia, Vol. 41, No. 1 (2014)
12
